About Eubiologics
Eubiologics is a company based in Seoul (South Korea) founded in 2012. Eubiologics has raised $7.5 million across 2 funding rounds from investors including ARGES and Global Health Investment Corporation. The company has 353 employees as of December 31, 2024. Eubiologics operates in a competitive market with competitors including Insmed, Affinivax, Eligo Bioscience, Lodo Therapeutics and Symbiomix Therapeutics, among others.
- Headquarter Seoul, South Korea
- Employees 353 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Eubiologics Co., Ltd.
-
Annual Revenue
$103.25 M (USD)55.35as on Dec 31, 2025
-
Net Profit
$33.7 M (USD)154.77as on Dec 31, 2025
-
EBITDA
$30.11 M (USD)163.22as on Dec 31, 2024
-
Total Equity Funding
$7.5 M (USD)
in 2 rounds
-
Latest Funding Round
$28.07 M (USD), Post-IPO
Apr 01, 2018
-
Investors
ARGES
& 1 more
-
Employee Count
353
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Eubiologics
Eubiologics is a publicly listed company on the KRX with ticker symbol 206650 in South Korea, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Funding Insights of Eubiologics
Eubiologics has successfully raised a total of $7.5M across 2 strategic funding rounds. The most recent funding activity was a Post-IPO round of $28.07 million completed in April 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Eubiologics
Eubiologics has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include ARGES and Global Health Investment Corporation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
Global health technologies are catalyzed by this nonprofit organization.
|
Locked | Locked | Locked |
Investor details for Eubiologics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Eubiologics
Investment portfolio details for Eubiologics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Eubiologics
Detailed financials for Eubiologics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Eubiologics Comparisons
Peer comparison for Eubiologics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Eubiologics
Eubiologics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Insmed, Affinivax, Eligo Bioscience, Lodo Therapeutics and Symbiomix Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of small molecule inhibitors for rare lung diseases
|
|
| Locked | Locked | Locked |
Technology-based conjugate vaccines against infectious diseases are developed.
|
|
| Locked | Locked | Locked |
In vivo gene editing technology is developed for microbiome modulation.
|
|
| Locked | Locked | Locked |
Developer novel therapeutics to treat resistant infectious diseases and cancers using AI
|
|
| Locked | Locked | Locked |
Late-stage biopharma antibiotics for gynecological infections are developed.
|
|
| Locked | Locked | Locked |
Developer of vaccines for bacterial infections and cancer by using proprietary protein superglue technology
|
Detailed competitors of Eubiologics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Eubiologics
Complete news archive for Eubiologics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Eubiologics
Eubiologics was founded in 2012 and raised its 1st funding round 2 years after it was founded.
Eubiologics is headquartered in Seoul, South Korea.
Yeong Ok Baik is the current CEO of Eubiologics.
Eubiologics is a funded company, having raised a total of $7.5M across 2 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Eubiologics is 353.
Annual revenue of Eubiologics is $103.25M as on Dec 31, 2025.
EuBiologics is a Contract Research and Manufacturing Organization (CRMO) providing customized services for mammalian cell and microbial-derived biopharmaceutical from cell line development to GMP production and also developing its own portfolio of products. They specialize in vaccine development and also in the development of advanced biopharmaceuticals. The company also has a pipeline of vaccine products. Euvichol (Oral Cholera Prevention Vaccine) and CRM 197 (immunological transferring protein) have been launched and many others are in various stages of preclinical and clinical development.
Eubiologics's top competitors include Insmed, MaaT Pharma and Basilea.
Yes, Eubiologics is publicly traded on KRX under the ticker symbol 206650.
Eubiologics has 2 investors. Key investors include ARGES, and Global Health Investment Corporation.
The ticker symbol of Eubiologics is 206650 on KRX.